Abstract Number: 2867 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid Antibodies Promote the Release of Neutrophil Extracellular Traps: a New Mechanism of Thrombosis in the Antiphospholipid Syndrome
Background/Purpose: Antiphospholipid antibodies (aPL), especially those targeting beta-2-glycoprotein I, are known to activate endothelial cells, monocytes, and platelets, with prothrombotic implications. However, the interaction of…Abstract Number: 2868 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository Initial Analysis
Background/Purpose: APS ACTION International Clinical Database and Repository (“Registry”) was created to study the natural course of disease over 10 years in persistently aPL-positive patients…Abstract Number: 2869 • 2014 ACR/ARHP Annual Meeting
TLR7 Influences Autoreactive B Cell Selection in the Germinal Center
Background/Purpose: TLR7 is required for the generation of anti-RNA antibodies and excess TLR7 confers a SLE-like phenotype in mice. Recent studies have shown that TLR7…Abstract Number: 2870 • 2014 ACR/ARHP Annual Meeting
B Cell-Intrinsic Deletion of the Type 1 Interferon Receptor Does Not Impact the Development of Murine Lupus
Background/Purpose Type 1 interferon (IFN) is strongly implicated in lupus pathogenesis, and patients with SLE frequently express a “type 1 IFN gene signature”. Type 1…Abstract Number: 2871 • 2014 ACR/ARHP Annual Meeting
Break of Anergy in Human Autoreactive B Cells By T Helper Signals Restores B Cell Receptor Signaling Capacity and Is Dependent on Upregulation of CD45 Phosphatase Activity-a Possible Novel Mechanism of Breech of B Cell Tolerance in Rheumatic Diseases
Background/Purpose : We recently identified a human B cell population, which is naturally autoreactive and tolerized by functional anergy. This population was naïve, fully mature,…Abstract Number: 2872 • 2014 ACR/ARHP Annual Meeting
B-Cell Autoepitope and Tetramer Analysis Reveals Expansion of Apoptotic Autoantigen La and snRNP Reactive B Cells in BXD2 Mice
Background/Purpose Systemic lupus erythematous (SLE) is characterized by production of highly pathogenic IgG autoantibodies (autoAbs). While serum autoAb profiling is standard, it remains challenging to…Abstract Number: 2873 • 2014 ACR/ARHP Annual Meeting
Epratuzumab Induces Broad Inhibition of B Cell Receptor Proximal Signaling but Has Opposing Effects on Distal Signaling in B Cell Subsets: A Profile of Effects on Functional Immune Signaling By Single Cell Network Profiling
Background/Purpose Epratuzumab is a humanized monoclonal antibody targeting the B cell-specific protein CD22 and is in Phase 3 clinical trials in patients with systemic lupus…Abstract Number: 2874 • 2014 ACR/ARHP Annual Meeting
Pro-Inflammatory FcRL4+ Memory B Cells in Joints of RA Patients: Immunoglobulin Gene Characteristics and Antigen Specificity
Background/Purpose: Our recent findings identified a subset of pro-inflammatory memory B cells in the RA synovium characterized by the expression of the surface protein…Abstract Number: 2835 • 2014 ACR/ARHP Annual Meeting
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Sirukumab in Patients with Active Lupus Nephritis
Background/Purpose: IL-6 is a pro-inflammatory cytokine that is over-expressed in lupus nephritis(LN). This proof-of-concept study examined the efficacy and safety of sirukumab, an anti-interleukin-6…Abstract Number: 2836 • 2014 ACR/ARHP Annual Meeting
Effects of Blisibimod, an Inhibitor of B Cell Activating Factor, on Patient Reported Outcomes and Disease Activity in Patients with Systemic Lupus Erythematosus
Background/Purpose: To conduct secondary endpoint analyses of the effects of subcutaneously-administered blisibimod (A-623, AMG 623), an inhibitor of B-cell activating factor (BAFF), on patient-reported outcomes and…Abstract Number: 2837 • 2014 ACR/ARHP Annual Meeting
Induction of Clinical Remission By Low-Dose Interleukin-2 in Refractory SLE
Background/Purpose Interleukin-2 (IL-2) is crucial for the growth and survival of regulatory T cells (Treg), and thus for the control of autoimmunity. In previous studies…Abstract Number: 2838 • 2014 ACR/ARHP Annual Meeting
Exploratory Analysis of Pharmacokinetic Effects of Atacicept in Patients with Moderate to Severe Systemic Lupus Erythematosus
Background/Purpose: Atacicept is a fusion protein that inhibits B-cell stimulating factors BLyS and APRIL. We previously reported the clinical effects of atacicept in lupus patients…Abstract Number: 2839 • 2014 ACR/ARHP Annual Meeting
BCL-2 As a Potential Therapeutic Target in Human Lupus Tubulointerstitial Inflammation
Background/Purpose Lupus nephritis (LuN) is the most common, severe manifestation of systemic lupus erythematosus (SLE). We have previously shown that glomerulonephritis appears to be a…Abstract Number: 2840 • 2014 ACR/ARHP Annual Meeting
Targeting the RhoA-Rock Pathway to Reverse T Cell Dysfunction in SLE
Background/Purpose Aberrant expansion of TH-17 cells and deregulated production of IL-17 and IL-21 are involved in the pathogenesis of SLE. Production of IL-17 and IL-21…Abstract Number: 2841 • 2014 ACR/ARHP Annual Meeting
Identifying Novel Lupus Severity Risk Variants through Identification of Alleles with High Ethnic Variability Worldwide
Background/Purpose: Substantial epidemiologic evidence demonstrates that SLE disproportionately affects minority patients in terms of incidence, prevalence, and disease severity. European ancestry has been associated with…
ACR Meeting Abstracts